A protein (pre-haptoglobin-2) that reversibly modulates tight junction permeability in the intestinal epithelium. Identified by Alessio Fasano in 2000, zonulin is the only known physiological regulator of intestinal paracellular permeability and has become the most widely used biomarker for "leaky gut" — a state of increased intestinal permeability implicated in autoimmune, neuropsychiatric, and metabolic diseases.
Mechanism
- Zonulin binds to PAR2 (protease-activated receptor 2) and EGFR (epidermal growth factor receptor) on the apical surface of enterocytes.
- This triggers intracellular signaling (phospholipase C -> PKC-alpha) that leads to cytoskeletal rearrangement and displacement of ZO-1 from the tight junction complex.
- The tight junction opens transiently, allowing paracellular passage of macromolecules, antigens, and bacteria.
- The process is reversible — zonulin-mediated opening is self-limiting under normal conditions, with tight junctions re-sealing within minutes to hours.
Triggers of Zonulin Release
Two primary stimuli trigger zonulin secretion from enterocytes:
- Gliadin (wheat gluten peptide) — Binds CXCR3 on enterocytes, triggering MyD88-dependent zonulin release. This is the mechanistic basis for gluten-induced permeability in celiac disease and non-celiac gluten sensitivity.
- Small intestinal bacterial exposure — Bacterial colonization of the small intestine (normally low-bacterial) triggers zonulin release as a defensive flushing mechanism. Dysbiosis with small intestinal bacterial overgrowth (SIBO) causes chronic zonulin elevation.
Clinical Significance
Elevated serum zonulin is reported across a striking range of conditions, all sharing intestinal barrier dysfunction as a pathogenic feature:
- Celiac disease — The condition where zonulin was discovered; elevated zonulin mediates gluten-triggered permeability.
- Type 1 diabetes (T1D) — Zonulin elevation precedes clinical onset, suggesting barrier dysfunction contributes to autoimmune triggering.
- Schizophrenia — Elevated zonulin correlates with symptom severity and markers of systemic inflammation, supporting the gut-brain barrier disruption model.
- Chronic kidney disease (CKD) — Elevated zonulin contributes to uremic toxin translocation from the gut.
- Inflammatory bowel disease — Elevated in active Crohn's disease and ulcerative colitis.
- Obesity and metabolic syndrome — Zonulin elevation correlates with BMI and insulin resistance.
Interpretive Cautions
- Assay variability — Commercial zonulin ELISA kits have been criticized for detecting multiple proteins (including complement C3 and properdin), not just pre-haptoglobin-2. Results must be interpreted with awareness of assay specificity.
- HP2 genotype dependency — Only individuals carrying the HP2 allele (haptoglobin 2) produce zonulin. HP1-1 homozygotes do not secrete zonulin, which may explain population variability in permeability responses.
- Correlation vs. causation — Elevated zonulin is consistently associated with disease states, but whether it drives pathology or merely marks existing barrier damage remains debated for most conditions outside celiac disease.
Cross-References
- intestinal permeability — The barrier function zonulin modulates
- blood brain barrier — Also affected by zonulin-family peptides
- calprotectin — Complementary biomarker (inflammation vs. permeability)
- biomarkers — Zonulin as clinical marker
- schizophrenia, type 1 diabetes, chronic kidney disease — Conditions with elevated zonulin